New: Aston Villa transfer dealsheet - incomings and outgoings:
Intent on keeping Rogers, wanting Martinez to stay, adhering to a finance plan, key positions to recruit (a pacey winger), but are also dependent on who leaves.
Free to read @TheAthleticFC#AVFC
https://t.co/kqhxa2aT9G
Yesterday was Clinical Trials Day, and we want to take a moment to recognize the incredible patients and families participating in clinical research — especially those involved in the gallium maltolate Expanded Access Program for recurrent glioblastoma.
Clinical progress does not happen without patients willing to step forward during some of the most difficult moments of their lives. Every scan, every follow-up, every shared experience contributes to a better understanding of this disease and helps inform future treatment decisions for the broader glioblastoma community.
To the patients, caregivers, physicians, and advocates participating in research and Clinical Trials: thank you for advancing hope, knowledge, and progress for others facing GBM.
Your courage matters far beyond your own journey. 💙
#ClinicalTrialsDay #Glioblastoma #GBM #BrainTumorResearch #ClinicalResearch #ExpandedAccess #GlioblastomaAwareness #NeuroOncology #CancerResearch #BrainTumorCommunity
#IBAI with @Heidyll increasing his Truetide holding to 28.2% both he and Truetide need their 29.35% concert party holding in IBAI to realise the huge (IBAI) gains we all expect in the short/medium term.
#IBAI
"The combination of Group-wide cost savings, Kirkstall's accelerating sales trajectory and the imminent launch of IB's next-generation platforms creates a clear path to profitability in 2026."
Annual Report for the Year Ended 31 December 2025
https://t.co/YdJm4aNvUD
#IBAI
Annual results due on or before 30/4. Then “throughout May we explore how advanced imaging can bring greater clarity to complex cases.”
All part of growing revenues and profitability in the new financial year.
This #GrayMay, we’re launching a focused campaign on advancing brain tumor imaging through quantitative MRI.
From leakage correction to automated Fractional Tumor Burden (FTB) maps, we’ll highlight tools designed to reduce ambiguity and support more confident clinical decision-making.
Follow along throughout May as we explore how advanced imaging can bring greater clarity to complex cases.
#PerfusionMRI #BrainTumorImaging #Neuroradiology #Oncology
It's time brain tumor imaging moves beyond qualitative assessment.
Standardized fractional tumor burden (FTB) maps from @ImgBiometrics, built on IB Neuro and IB Delta T1 maps, automatically deliver quantitative, reproducible, and clinically actionable insights—
Looking forward to the discussions (and tough cases) at #ASFNR VEA this October in Newport Beach.
Imaging interpretation turnaround times more than double over a decade https://t.co/zlLENwbsvE
MR is up 256%. CT is up 318%. Radiologists are maxed out.
@ImgBiometrics delivers fully automated quantitative maps — objective, reproducible, and available within seconds of acquisition.
As radiology faces soaring volume and shrinking workforce capacity, IB provides what the system can’t: speed, standardization, and true scalability.
If the specialty has hit its limit, the answer isn’t more hours — it’s automation that removes variability and accelerates interpretation.
Professor Kathleen Schmainda will present to the NCI Quantitative Imaging Network (QIN) on advanced perfusion imaging on March 30.
The presentation is titled: “Innovation to Impact: How IB [@ImgBiometrics] Brought Perfusion MRI Tools to Clinical and Trial Deployment.”
The Quantitative Imaging Network (QIN) is a major program of the National Institutes of Health (NIH/NCI) designed to accelerate the development, validation, and clinical translation of quantitative imaging tools for cancer diagnosis, treatment planning, and therapeutic response assessment.
IB is a long-standing QIN contributor.
#QIN #NIH #QuantitativeImaging #PerfusionMRI #DeltaT1 #FTBmaps #IBNeuro #BrainTumors #NeuroOncology #Radiology #Neurosurgery #ClinicalTrials #MedicalImaging
Exciting to see advanced imaging translated into real-world care.
At #ISMRM, Dr. Max Krucoff showcased how #FTB maps guide biopsy targeting and #DeltaT1 quantifies LITT outcomes in glioma patients.
This is the future of objective MRI.
#BrainTumor#Neurosurgery#MRI
Congratulations to Dr. Mona Al‑Gizawiy of the Medical College of Wisconsin on securing a new NIH R01 award—and to announce our role as a sub‑award recipient on this important project. This five‑year, $3M grant will accelerate the understanding of gallium maltolate (GaM), a promising oral therapy targeting some of the most aggressive pediatric brain cancers.
Under Dr. Al‑Gizawiy’s leadership, the pre-clinical project will advance the combination of GaM with radiation therapy, building on early evidence that GaM can enhance treatment effectiveness. IB will support this work with our FDA‑cleared quantitative MR imaging platform—including our advanced Fractional Tumor Burden (FTB) maps—which delivers standardized, highly sensitive measures of tumor response. This capability is essential for evaluating emerging therapies and represents a key differentiator in the neuro‑oncology imaging market.
“IB’s quantitative imaging gives us an early and reliable window into how tumors respond to treatment—something conventional scans simply can’t match,” said Dr. Al‑Gizawiy.
IB packages pre-clinical imaging workflows to create a unified imaging ecosystem that strengthens our position across research and clinical markets. This initiative supports long‑term growth by expanding IB’s footprint in translational research and multi‑site trials.
#PediatricBrainCancer #ChildhoodCancerResearch #PediatricOncology #BrainTumorResearch #DIPG #Glioblastoma #ATRT #HighGradeGlioma #ftbmaps
#IBAI what are the benefits of yesterday's award of a new $3m NIH grant to the Medical College of Wisconsin & a sub award to IBAI, in relation 2 the likelihood of another company advancing the completed phase I GaM trial into a new phase II trial?
https://t.co/dmx8pcPKhn